10 completed, 1 terminated, 1 withdrawn. 5 Phase 1, 5 Phase 2, 3 Phase 3, 1 Not applicable.
By phase and status
Follow motavizumab: new trials by email Literature Review of motavizumab trials Research Report on motavizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
Motavizumab, Placebo - Wheezing | Phase 3 | Withdrawn | MedImmune LLC | | 2010-10-01 | 2012-08-01 |
A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557
MEDI-557 - Healthy | Phase 1 | Completed | MedImmune LLC | 31 | 2007-12-01 | 2011-11-23 |
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
Motavizumab, Placebo - Participants Less Than 12 Months of Age With RSV Illness | Phase 2 | Terminated | MedImmune LLC | 12 | 2007-03-20 | 2021-08-17 |
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
Motavizumab, Placebo - RSV Illness in ≤12 Months of Participants | Not applicable | Completed | MedImmune LLC | 118 | 2007-01-10 | 2021-08-27 |
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Motavizumab, palivizumab, Palivizumab, motavizumab, Motavizumab - Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or | Phase 2 | Completed | MedImmune LLC | 260 | 2006-04-01 | 2012-12-11 |
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
Motavizumab, Palivizumab - Congenital Heart Disease | Phase 2 | Completed | MedImmune LLC | 1236 | 2005-10-01 | 2012-02-16 |
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
motavizumab (MEDI-524), palivizumab 15 mg/kg - Motavizumab Administration for a Second Season for RSV Prophylaxis | Phase 1 / Phase 2 | Completed | MedImmune LLC | 136 | 2005-05-01 | 2013-05-22 |
MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
Motavizumab, Placebo - Healthy | Phase 3 | Completed | MedImmune LLC | 2127 | 2004-11-15 | 2022-01-05 |
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
motavizumab (MEDI-524), palivizumab - Respiratory Syncytial Virus Infections | Phase 3 | Completed | MedImmune LLC | 6635 | 2004-11-01 | 2013-08-28 |
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection
Motavizumab, Placebo - Respiratory Syncytial Virus Prophylaxis | Phase 1 | Completed | MedImmune LLC | 31 | 2004-03-01 | 2021-10-08 |
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
Medi-524 - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Completed | MedImmune LLC | 217 | 2004-02-01 | 2008-07-28 |
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults
MEDI-524 (Numax-TM) - Respiratory Syncytial Virus Infections | Phase 1 | Completed | MedImmune LLC | 30 | 2003-11-01 | 2009-01-29 |
Conditions studied
Respiratory Syncytial Virus Infections (4) · Heart Defects, Congenital (1) · Premature Birth (1) · Respiratory Sounds (1)
Sponsors
MedImmune LLC (12)
Countries
United States (7) · Chile (5) · Australia (3) · New Zealand (3) · Argentina (2) · Austria (2) · Brazil (2) · Bulgaria (2) · Canada (2) · Czechia (2) · Denmark (2) · France (2) · Germany (2) · Hungary (2) · Israel (2)
Top investigators
M. Pamela Griffin, M.D. (3) · Genevieve Losonsky, MD (2) · Genevieve A Losonsky, MD (1) · M Pamela Griffin, M.D. (1) · M Pamela Griffin, MD (1) · Pamela Griffin, 301-398-0000 (1) · Pamela Griffin, M.D. (1)
Results publications
PMID 19258920, PMID 20008423, PMID 20525274, PMID 24080653, PMID 24356256, PMID 26511956